The evidence supports a precise answer: tirzepatide benefits are clearest for weight reduction and glucose control. A branded version also has a U.S. indication for moderate-to-severe obstructive sleep apnea in adults with obesity. Randomized trials have reported favorable outcomes in obesity-related heart failure with preserved ejection fraction, metabolic liver disease, blood pressure and lipids, but those findings are not all approved uses.
Tirzepatide activates both GIP and GLP-1 receptors. That dual action affects appetite, food intake and glucose-dependent insulin signaling. The useful question is not whether it has one broad health benefit. It is which outcome was measured, in whom, for how long, and against what comparator.
Tirzepatide benefits at a glance
| Outcome | Named evidence | What the trial reported | U.S. status as of September 2026 |
|---|---|---|---|
| Body weight | SURMOUNT-1, NEJM 2022 | Mean change at 72 weeks was -15.0%, -19.5% and -20.9% across the three dose groups, versus -3.1% with placebo | Zepbound indication for long-term weight reduction in qualifying adults |
| Blood glucose in type 2 diabetes | SURPASS-2, NEJM 2021 | Mean A1C change at 40 weeks was -2.01 to -2.30 percentage points, versus -1.86 with semaglutide 1 mg | Mounjaro indication for glucose control in adults with type 2 diabetes |
| Obstructive sleep apnea with obesity | SURMOUNT-OSA, NEJM 2024 | Placebo-adjusted AHI differences were -20.0 and -23.8 breathing events per hour in the two 52-week trials | Zepbound indication for moderate-to-severe OSA in adults with obesity |
| HFpEF with obesity | SUMMIT, NEJM; online 2024, print 2025 | Cardiovascular death or worsening heart failure occurred in 9.9% with tirzepatide and 15.3% with placebo | Trial finding, not a separate tirzepatide indication |
| Major cardiovascular events in type 2 diabetes and ASCVD | SURPASS-CVOT, NEJM 2025 | Events occurred in 12.2% with tirzepatide and 13.1% with dulaglutide; tirzepatide was noninferior, not superior | Branded Mounjaro indication since August 27, 2026: reducing the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, or at high risk of it (the FDA's action letter of that date); what that label change does and doesn't mean |
| MASH with moderate or severe fibrosis | SYNERGY-NASH, NEJM 2024 | MASH resolved without worsening fibrosis in 44% to 62% across dose groups, versus 10% with placebo at 52 weeks | Phase 2 finding, not a tirzepatide indication |
| Blood pressure and lipids | SURMOUNT-1 secondary analyses | Pooled placebo-adjusted blood-pressure differences were -6.8 mm Hg systolic and -4.2 mm Hg diastolic; lipid measures also moved favorably | Secondary outcomes, not separate indications |
The table is deliberately strict. An indication tells clinicians which use a branded product has been reviewed for. A trial finding says what happened in a defined study population. It may be important without becoming a reason to prescribe the medication for everyone.
Weight and glucose have the deepest evidence
SURMOUNT-1 enrolled 2,539 adults with obesity, or overweight plus a weight-related complication, without diabetes. Its headline result was a mean 20.9% weight reduction at 72 weeks in the 15 mg group, compared with 3.1% on placebo. The dedicated guide to tirzepatide weight-loss results explains the responder thresholds and what an average cannot predict for one person.
SURPASS-2 studied 1,879 adults with type 2 diabetes taking metformin. Tirzepatide lowered A1C by an estimated 2.01 to 2.30 percentage points across study doses, compared with 1.86 points for semaglutide 1 mg. This was a head-to-head glucose-control trial, not a comparison of every current formulation or dose. Tirzepatide for type 2 diabetes covers that evidence in clinical context.
Semaglutide remains a relevant alternative because it has its own evidence base, prescribing profile and tolerability considerations. The better choice is not determined by a single average from SURPASS-2.
Sleep apnea is an established use in a specific group
SURMOUNT-OSA included two trials of adults with obesity and moderate-to-severe obstructive sleep apnea. After 52 weeks, the apnea-hypopnea index fell by 25.3 events per hour with tirzepatide versus 5.3 with placebo in the trial without positive airway pressure at baseline. In the trial with positive airway pressure, the changes were 29.3 and 5.5 events per hour.
That evidence led to the branded indication for adults who have both obesity and moderate-to-severe OSA. It does not turn tirzepatide into a general sleep aid, and it does not make airway treatment decisions automatic. The tirzepatide sleep-apnea evidence explains who was studied and how AHI was measured.
Heart failure outcomes are not the same as broad heart protection
SUMMIT studied 731 people with obesity and HFpEF. Over a median 104 weeks, cardiovascular death or a worsening heart-failure event occurred in 9.9% of the tirzepatide group and 15.3% of the placebo group, a hazard ratio of 0.62. The health-status score also improved by 6.9 points more with tirzepatide at 52 weeks. Those numbers apply to obesity-related HFpEF, not to every form of heart disease.
SURPASS-CVOT answered a different question in 13,165 analyzed participants with type 2 diabetes and established atherosclerotic cardiovascular disease. Major events occurred in 12.2% with tirzepatide and 13.1% with dulaglutide. The result met noninferiority but not superiority. That supports cardiovascular safety relative to an active GLP-1 comparator; it does not establish a broad cardiovascular-risk-reduction indication.
Liver, blood-pressure and lipid findings remain trial outcomes
SYNERGY-NASH was a 190-person phase 2 trial in biopsy-confirmed MASH with stage F2 or F3 fibrosis. At 52 weeks, MASH resolution without worsening fibrosis occurred in 44%, 56% and 62% across the tirzepatide groups, compared with 10% on placebo. Improvement by at least one fibrosis stage without worsening MASH occurred in 51% to 55% versus 30%. The investigators called for larger and longer trials.
Blood pressure moved in the same favorable direction as weight in SURMOUNT-1. A 2024 analysis in Heart found net reductions versus placebo of 6.8 mm Hg systolic and 4.2 mm Hg diastolic at 72 weeks; weight change explained most of the difference. Triglycerides, non-HDL cholesterol and HDL cholesterol were secondary measures that also improved in the original trial. None of this makes tirzepatide a substitute for a blood-pressure or lipid medication.
What the evidence means for a compounded prescription
The trials above studied branded tirzepatide under controlled protocols. Promise's tirzepatide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. FDA explains that it does not review compounded drugs for safety, effectiveness or quality before they reach patients.
A licensed provider may still prescribe a compounded formulation when it is clinically appropriate; that decision belongs to the patient and the reviewing provider. Trial averages are only one input. Medical history, current medications, contraindications, treatment goal and tolerance all matter, and tirzepatide side effects deserve the same attention as outcomes.
At Promise, a licensed provider reviews every request, and not everyone qualifies. That review is where population-level evidence becomes an individual decision.